Claim Missing Document
Check
Articles

The Effect of Phaleria macrocarpa Bioactive Fraction (Proliverenol) Supplementation on Liver Damage in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD) Irsan Hasan; Saut Horas Hatoguan Nababan; Raymond R. Tjandrawinata; Danang Agung Yunaidi; Liana W. Susanto
MEDICINUS Vol. 38 No. 7 (2025): MEDICINUS
Publisher : PT Dexa Medica

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.56951/a4ba3z37

Abstract

Liver is considered one of the most vital organs, acting as the center of metabolism of nutrients and excretion of waste products. Non-alcoholic fatty liver disease (NAFLD) is one of the main causes of chronic liver disease. The management of NAFLD continues to evolve, and clinicians are currently faced with a variety of alternative options, both nonpharmacotherapeutic and pharmacotherapy, to avoid more severe liver disease. Phaleria macrocarpa (Scheff.) Boerl., namely, mahkota dewa in Indonesia, has been used empirically to treat cancer, allergy, and diabetes mellitus. Proliverenolis a proprietary bioactive fraction derived from the dried fruit of Phaleria macrocarpa (Scheff.) Boerl. Proliverenol was reported to have hepatoprotective, anti-inflammatory, antioxidant, and antifibrotic effects. The study found that Proliverenol bioactive fraction, at a dosage of 1000 mg twice daily for at least 4 weeks of treatment, is effective in improving liver damage with a good safety profile.
Treatment for Intermediate-Stage Hepatocellular Carcinoma: Current Practice and Outcome in Real World Study Hasan, Irsan; Loho, Imelda Maria; Lesmana, Cosmas Rinaldi A.; Gani, Rino Alvani; Siregar, Lianda; Waspodo, Agus Sudiro; Lesmana, Laurentius A
The Indonesian Journal of Gastroenterology, Hepatology, and Digestive Endoscopy Vol 23, No 1 (2022): VOLUME 23, NUMBER 1, April 2022
Publisher : The Indonesian Society for Digestive Endoscopy

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (434.834 KB) | DOI: 10.24871/231202224-28

Abstract

Background: Intermediate-stage hepatocellular carcinoma (HCC) is a very heterogeneous disease. The first line treatment for this group is transarterial chemoembolization (TACE), however, in clinical practice, not all patients are suitable for TACE. We aim to evaluate current treatment practice and outcome of patients with intermediate-stage HCC.Methods: HCC patients database from 2013 to 2016 in Cipto Mangunkusumo Hospital and Dharmais Cancer Hospital were retrospectively analyzed. Patients with intermediate-stage HCC were included in this study.Results: A total of 456 patients were diagnosed with HCC, but only 151 (33.1%) patients with intermediate-stage HCC were included. Men outnumbered women in a ratio of 3:1. The most common etiology for HCC was hepatitis B virus (HBV) infection, which accounted for 55% of patients. Fifty-two patients (34.4%) were treated with TACE as first-line treatment. Sixty-seven patients (44%) were given best supportive care due to ineligibility for TACE. Frequency of TACE varied from one to eleven times. Overall median survival was 617 days (1.7 years). One-year survival for patients undergoing TACE and liver resection was 47% and 60%, respectively. We did not compare the survival between any treatment groups because the number of patient in each group is not sufficient to be statistically analyzed.Conclusion: Only 34.4% of patients with intermediate-stage HCC was treated with TACE as first-line treatment. An improvement in the treatment strategy should be done for HCC patients in Indonesia.
Sarcopenia is Associated with Poor Performance Status in Indonesian Patients with Hepatocellular Carcinoma Koncoro, Hendra; Hasan, Irsan; Lesmana, C Rinaldi; Aditama, Humala Prika; Salamah, Thariqah; Rizka, Aulia; Wahyudi, Edy Rizal; Shatri, Hamzah; Teng, Wei
The Indonesian Journal of Gastroenterology, Hepatology, and Digestive Endoscopy Vol 23, No 1 (2022): VOLUME 23, NUMBER 1, April 2022
Publisher : The Indonesian Society for Digestive Endoscopy

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (614.006 KB) | DOI: 10.24871/231202217-23

Abstract

Background: Sarcopenia has a notable impact on the prognosis of hepatocellular carcinoma (HCC). The prevalence of sarcopenia in patients with HCC is relatively high, with studies reporting rates between 39% and 41.7%. A substantial proportion of individuals diagnosed with HCC also exhibit muscle wasting and reduced muscle function. This study aims to determine the prevalence of sarcopenia in Indonesian patients with HCC (based on the Japanese Socuety of Hepatology (JSH) JSH criteria) and to examine its correlation with poor performance status.Methods: We performed a cross-sectional study of 85 HCC patients between January and October 2021). The skeletal muscle index at L3 (L3 SMI) was measured on CT scans (applying JSH cut-offs for sarcopenia). Clinical data, including Eastern Cooperative Oncology Group (ECOG) performance status, were collected. Bivariate analyses and logistic regression were performed to identify factors associated with sarcopenia.Results: A total of 85 HCC patients (median age: 52 years) were included in the analysis. Sarcopenia was observed in 49.4% of the cohort. Bivariate analysis revealed a statistically significant association between sarcopenia and an ECOG performance status of 2+ (p = 0.003), as well as a MELD-Na score of ≥15 (p = 0.023). In multivariate analysis, poor ECOG-PS remained independently associated with sarcopenia (adjusted OR 4.17; 95% CI 1.50–11.56, p = 0.006).Conclusion: Sarcopenia is highly prevalent among Indonesian HCC patients, and it is strongly associated with poor ECOG performance status. 
Tenofovir Alafenamide (TAF) as Long-Term Therapy for Chronic Hepatitis B: Is It the Best Choice? Hasan, Irsan
The Indonesian Journal of Gastroenterology, Hepatology, and Digestive Endoscopy Vol 23, No 3 (2022): VOLUME 23, NUMBER 3, December 2022
Publisher : The Indonesian Society for Digestive Endoscopy

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.24871/2332022173

Abstract

-
Co-Authors -, Gunawan - -, Gunawan - Abdul Aziz Rani Abdul Aziz Rani Abdul Rahman M Aditama, Humala Prika Agus Sudiro Waspodo Agus Waspodo Agustinus, Taolin Alessa Fahira Ali Sulaiman Ali Sulaiman Alvin Nursalim Alvin Nursalim Amanda Trixie Hardigaloeh Anandhara Indriani Khumaedi Anandhara Indriani Khumaedi, Anandhara Indriani ANDI UTAMA Andi Utama Andri Sanityoso Andri Sanityoso Andri Sanityoso Sulaeman Andri Sanityoso Sulaiman Aprilicia, Gita Ari Fahrial Syam Arnold Hasahatan Harahap Asep Saepul Rohmat Asep Saepul Rohmat, Asep Saepul Aulia Rizka, Aulia Azzaki Abubakar Azzaki Abubakar, Azzaki Baiq Kirana DN Mandasari Bambang Sutopo C Rinaldi A Lesmana C. Martin Rumende C. Martin Rumende, C. Martin Chyntia Olivia M. Jasirwan Chyntia Olivia Maurine Jasirwan, Chyntia Olivia Maurine Cleopas Martin Rumende Dadang Makmun Danang Agung Yunaidi Deskian Kostermans Deskian Kostermans, Deskian Diah Iskandriati E Mudjadid E. Mudjaddid A. Siswanto Deddy N.W.Achadiono Hamzah Shatri Edi Mulyana Edi Mulyana, Edi Edy Rizal Wahyudi Ening Krisnuhoni Eric Daniel Tenda Erni Erfan, Erni Esthika Dewiasty, Esthika Evy Yunihastuti Felix F Widjaja, Felix F FX Pridady Gita Aprilicia Gita Aprilicia Griscalia Christine Griskalia Christine Gunawan - - Guntur Darmawan H. M.S. Noer Hamzah Shatri Hamzah Shatri Hanif, Muhammad Yusuf Hardigaloeh, Amanda Trixie Hendra Koncoro Hilman Zulkifli Amin Idrus Alwi Idrus Alwi Idrus Alwi Ignatius Bima Prasetya, Ignatius Bima Iman Firmansyah Iman Firmansyah Imelda Maria Loho Imelda Maria Loho, Imelda Maria Indra Marki Indra Marki Jasirwan, Chyntia Olivia M Jeffry Beta Tenggara Juferdy Kurniawan Karmel Tambunan Kartika, Ronald Winardi Kemal F Calista Kemal Fariz Kalista Kemal Fariz Kalista Kemal Fariz Kalista Kemal Fariz Kalista, Kemal Fariz L A Lesmana L. A. Lesmana Laniyati Hamijoyo, Laniyati Laurentius A Lesmana Laurentius A Lesmana, Laurentius A Laurentius Lesmana Laurentius Lesmana Leonard Nainggolan Liana W. Susanto Lianda Siregar Lies Luthariana Lies Luthariana Lutfie Lutfie, Lutfie Marcellus Simadibrata Marcellus Simadibrata Marcellus Simadibrata Marcellus Simadibrata Marcellus Simadibrata Marcellus Simadibrata Martha Iskandar Maryati Surya Maulana Suryamin, Maulana Mondrowinduro, Prionggo Muhammad Sjaifoellah Noer Muhammad Yamin Lubis Muhammad Yamin Lubis, Muhammad Yamin Muhammad Yusuf Hanif Murdani Abdullah Murdani Abdullah Murdani Abdullah Murdani Abdullah Nababan, Saut Horas H. Nafrialdi Nafrialdi Nurul Akbar Nurul Akbar Paramita Khairan, Paramita Paulus Kusnanto Prionggo Mondrowinduro Pudji Rahardjo Pudji Rahardjo Raymond R. Tjandrawinata Rino A Gani Rino A Gani Rino A. Gani Rino Alvani Gani Rino Alvani Gani Rino Alvani Gani Rino Alvani Gani Rino Alvani Gani Rino Alvani Gani Rino Alvani Gani Rino Alvani Gani Rino Alvani Gani Rino Alvani Gani Rino Alvani Gani Ruswhandi - Ruswhandi -, Ruswhandi Salius Silih Sartika, Katarina Dewi Saut HH Nababan Saut Horas H. Nababan Saut Horas Hatoguan Nababan Saut Horas Hatoguan Nababan Saut Horas Hatoguan Nababan Seruni Tyas Khairunissa Silmi Mariya Siti Setiati Sjaifoellah Noer Soemarno Soemarno Soemarno Soemarno Suhendro Suhendro Suhendro Suwarto Suhendro Suwarto, Suhendro Sulaeman, Andri Sanityoso Suradji, Eka Widrian Susan Tai Suzanna Ndraha Syahrizal Syarif Taolin Agustinus Teguh H. Karjadi Teguh H. Karjadi, Teguh H. Telly Kamelia Tendean, Marcel Teng, Wei Teressa, Maria THARIQAH SALAMAH, THARIQAH Unggul Budihusodo Wiguna, Candra Wijaya, Indra Wismandari Wisnu Yaldiera Utami Yaldiera Utami, Yaldiera Yong, Bernard Jonathan Christian Zulkifly, Steven